Three Charged After $2 Million Peptide and Steroid Seizure in Victoria

An eight-month joint investigation by the Australian Border Force, the Therapeutic Goods Administration, and Victoria Police has resulted in the seizure of approximately $2 million worth of peptides, steroids, and other performance and image enhancing drugs. Three Victorians have been charged with importing prohibited goods.

How the Investigation Unfolded

The operation began in August 2025 when border officers intercepted 640 vials of illegal substances in air cargo shipments. Further investigation revealed that dozens of similar consignments had already been delivered to the same recipient, suggesting an established importation network.

In March 2026, officers executed search warrants at properties in Melbourne's west, where they seized more than 10,000 vials, 600 tablets, cannabis seeds, and electronic devices. A 47-year-old man was charged with importing prohibited goods and later granted bail. Two additional suspects, a 46-year-old man and a 42-year-old woman, were charged following further raids and have been released on bail.

Enforcement Officials Warn of Broader Crackdown

ABF Commander Graeme Campbell said the case demonstrates the strength of joint operations between border and health agencies in stopping illegal drugs from reaching the community. TGA Head Professor Anthony Lawler warned that unapproved steroid and peptide products can be dangerous, particularly when injected, with risks including infection, contamination, and tissue damage.

The seizure is one of the largest peptide-related enforcement outcomes in recent Australian history, reflecting the TGA's formal designation of unapproved peptide products as a compliance priority for 2026-27.

Context: A Growing Enforcement Focus

The seizure fits a broader pattern of escalating TGA action against unapproved peptides. In January 2026, the TGA issued infringement notices to six individuals for alleged importation and unlawful advertising of therapeutic goods, including peptides. The agency's Compliance Principles for 2026-27 explicitly identify peptides, alongside medicinal cannabis, vaping goods, and weight-loss medicines, as priority enforcement areas.

A June 2026 newsGP poll found that 65% of GPs reported increased patient interest in peptide products, underscoring the demand that enforcement agencies are now contending with. Health authorities have reminded the public that peptide products must be approved and regulated in Australia before use, and that purchasing from unregulated online sources carries significant health risks.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.